Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study.
about
Atherosclerosis and infection: is the jury still not in?Risk factors in coronary atherosclerosis athero-inflammation: the meeting pointThe role of inflammation and infection in the pathogenesis and evolution of coronary artery diseaseChlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studiesRole of infectious and immune factors in coronary and cerebrovascular arteriosclerosisInflammation, infection and antimicrobial therapy in coronary heart disease--where do we currently stand?The importance of the gastrointestinal system in the pathogenesis of heart failure.Potential infectious etiologies of atherosclerosis: a multifactorial perspectiveCardiac protection by pharmacological modulation of inflammation.The macrolides.The role of infection in the genesis and complications of atherosclerosis.Role of antibiotics for the prevention of cardiovascular disease.Chlamydia pneumoniae resists antibiotics in lymphocytes.The role of infection in the pathogenesis of cardiovascular disease.Infectious etiology of vasculitis: diagnosis and management.Influenza and cardiovascular disease: is there a causal relationship?Antibiotic trials for coronary heart disease.Use of macrolides and tetracyclines for chronic inflammatory diseases.Influenza and atherosclerosis: vaccination for cardiovascular disease prevention.Managing Cardiovascular Risk of Macrolides: Systematic Review and Meta-Analysis.Buerger disease, smoking, and periodontitis.Chlamydophila pneumoniae infection and cardiovascular diseaseHospitalized Infection as a Trigger for Acute Ischemic Stroke: The Atherosclerosis Risk in Communities Study.A meta-analysis of antibiotic use for the secondary prevention of cardiovascular diseasesTelithromycin treatment of chronic Chlamydia pneumoniae infection in C57BL/6J micePeriodontal bacteremia and various vascular diseases.Possibilities for therapeutic interventions in disrupting Chlamydophila pneumoniae involvement in atherosclerosis.Increased infiltration of Chlamydophila pneumoniae in the vessel wall of human veins after perfusion.Chlamydial bacteriophage: No role in acute coronary events?Chlamydia pneumoniae--induced macrophage foam cell formation is mediated by Toll-like receptor 2.Chlamydophila pneumonia: Specific mRNA in aorta ascendens in patients undergoing coronary artery by-pass grafting.Antibiotics active against Chlamydia do not reduce the risk of myocardial infarction.A positive association of peripheral arterial occlusive disease (PAD) and Chlamydophila (Clamydia) pneumoniae.Update of antibiotic trials for secondary prevention of coronary heart disease.Clinical significance of Helicobacter pylori infection in patients with acute coronary syndromes: an overview of current evidence.Secondary prevention antibiotic treatment trials.Management After Myocardial Infarction.Chlamydia pneumoniae and Cardiovascular Disease.Chlamydia pneumoniaeand atherosclerosis
P2860
Q22241306-54601425-378E-46E8-9124-B8167C216DAFQ24793107-5CA837FD-D2CF-4EF8-BC01-22D8A3CF5840Q28193154-9FC390C7-5D79-47A0-A621-383D1A7BDC5DQ33905858-B12295C2-CDD8-4D08-B7EB-76BCD2C0B0D1Q33942966-D87F8B86-EAC3-477C-AF22-2FFA5AA62218Q34316462-6A031EDA-000D-4BFC-9699-9C04FD3DAAA6Q34429097-FED3F19A-7535-4830-970E-3C923E117280Q34465370-CEAFB0BB-6062-4197-9D80-229626F4DDC6Q34481804-8565A793-3626-42DB-85E2-786580B46F59Q34519125-ACC93AC8-0527-4FDB-92F2-FF535D0AD61CQ34605356-54D3E8D4-0DE2-4903-9567-5DDACB75A072Q34874476-50AD0BB1-53D5-40D9-AD0F-BEBE955A63E5Q35014062-0D25801B-7AB6-4C0F-B948-E0FA8115C6AEQ35080677-5ABE43F6-E932-45C5-AD82-0E9DFD845870Q35082005-26B40479-12E7-456F-BCE5-024871776CD3Q35733937-CC22CE8C-2EA4-4A4F-A9C6-146B76674BE7Q35733945-B9CDD866-C5F1-48E8-B742-C20D77807930Q35962028-79DDD29C-B8AC-4F0E-92FC-C3000882E504Q36040828-C70DFA30-E067-44CD-A13E-734D9563F5BDQ36342810-1994E85B-B9F6-450A-BA5D-324E72085946Q36679165-115DD569-D100-4562-9B17-5378A0DF6063Q36783331-620AC41F-9FA3-44D3-A3B2-5D893653A9F9Q36932553-05373657-A032-4CA6-9DDD-FF19739BCD44Q37098266-156DCAE4-FAD6-4D7E-9934-8250139CB8B3Q37568474-C96AAD34-69C1-440F-A8D2-E353DFC68AD0Q37623942-6D5AE942-ABC3-4A88-9567-70FB344DC37BQ37775097-4E5CD495-59B8-4A2E-A66B-82C892F2D1D9Q37857441-12B32D2E-624F-4637-BB93-86F9462CC4F0Q37858399-538E2159-E54C-4BF3-814F-D50AC536AA02Q37860795-579A276C-8EB3-4C85-A97E-77FB15518C18Q37861559-6A101E40-17C2-4F1F-B535-57E64E11488AQ37863427-A0CD90FE-B320-4B3E-8370-5D8212F16B52Q37864376-D7DFD308-356A-4010-9227-32B2DB5C551CQ37865389-F8012655-3F2D-4D9D-8289-FB635D095820Q38211000-8895ECCB-B9FF-413D-9EFE-732D6B53B56CQ43425170-A9AAB826-8EF4-47A7-8996-3620DCCBB937Q46071955-19035D07-6E7A-4EAD-8862-37583998D454Q51726841-63D83657-BB48-4E48-A455-D72714DE400CQ54063686-CAB2984F-32F1-484D-97F9-66E9D4A0F064
P2860
Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2000
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Randomized secondary preventio ...... results of the ACADEMIC study.
@en
Randomized secondary preventio ...... results of the ACADEMIC study.
@nl
type
label
Randomized secondary preventio ...... results of the ACADEMIC study.
@en
Randomized secondary preventio ...... results of the ACADEMIC study.
@nl
prefLabel
Randomized secondary preventio ...... results of the ACADEMIC study.
@en
Randomized secondary preventio ...... results of the ACADEMIC study.
@nl
P2093
P1433
P1476
Randomized secondary preventio ...... results of the ACADEMIC study.
@en
P2093
Anderson JL
Carlquist JF
Muhlestein JB
Pearson RR
Salunkhe K
P304
P356
10.1161/01.CIR.102.15.1755
P407
P577
2000-10-01T00:00:00Z